Replies to post #112606 on Amarin Corp Plc (AMRN)

[tmac20]

Thanks for the insight. So are you prescribing V to your patients?

[rafunrafun]

What kind of medicine do you practice, and you prescribe Vascepa? If so, can you share any experiences?

Also, we have been fortunate to have JL post his take on Vascepa... I am sure that you read most or all of his posts. Do you have any difference in opinion from his?

[couldbebetter]

Obviously, some doctors are well informed. I appreciate your take on AMRN. My belief is that even if R-I has steller results, AMRN will really have to work very hard to get that message across to the very busy docors who as you say are bombarded by drug information all of the time. AMRN management has been consistant that Vascepa could lead to a "paradigm shift" in medicine on how to treat CVD. Can you share any experiences of unexpected side effects if you have given Vascepa to your patients?

[Biobillionair]

Perhaps your a better Doctor than investor...I hope so...

I don't see an issue getting over 10 dollars with 10-20 well within reach with good results.

Amarin should already be trading at these levels, the fact it isn't should concern you. I'm not trying to stifle your opinion but please be reminded a cardiovascular drug that causes a paradigm shift is worth >$100 Billion when it has the IP protection "V" has.

I don't see the science failing, I do see Amarin's cautions with FDA feelings being a huge issue with stakeholders being royally screwed. Today this game changer trade $3 million total dollars...that's not justified by any means when you consider the R-I trial is set-up to smash written SPA expectations.

Please continue to post your opinion.

BB

[ralphey]

AMRN has a lot of issues it has to get by to be a success. AS a Family Doc I used the drug a fair amount. Its trig lowering capacity is not significant. However, as you have said that may be irrelevant if the outcomes study reveals great results.

The current issues I see are;

If the drug were a booming success study probably would have already been stopped. That leaves us with the ff possibilities:

1.) Moderate success in general population ( best choice)
2.) Success only in subsets ( ie diabetics with high trigs low hdl - personally I think this is what we will see )
3.) No success

Lets look at all three

no success - then it reverts to the trigs >500 market where it doesnt do a very good job - and the company fails

success only in subsets - currently docs are prescribing the med based on an understanding that it is reducing CAD risk in people with trigs 200-500. If it proves only successful in subsets then the potential market actually shrinks from current usage - rx numbers will decline - as will the stock

Thus REDUCE IT must be a success in the general population - but wait - even if it is the last hurdle is that about 60- 70% of my Rx's for vascepa get returned from the insurance company indicating that the patient should use OTC omega 3. So if the study does show moderate success the insurance companies just substitute OTC omega 3 - and believe me no docs are going to spend any time fighting that battle - The study may ultimately have been named ...for the stocks value